DON'T LET THEIR ACNE BE THE FOCUS.

Introducing AKLIEF® (trifarotene) Cream, 0.005%. A new and innovative topical therapy for the treatment of acne vulgaris. Proven effective on facial and truncal acne.1

PROVEN EFFICACY IN TREATING
ACNE VULGARIS IN

2,000+

PATIENTS ENROLLED IN 2 CLINICAL TRIALS1

RAPID RESULTS.* Powerful EFFICACY. EXCELLENT TOLERABILITY.1

View Clinical Data

because clearer skin matters.

PIVOTAL STUDIES 1 & 2
The first large-scale, randomized, Phase 3 clinical trials to simultaneously evaluate a topical therapy for the treatment of both moderate facial and truncal acne vulgaris.

Study 18251: Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of trifarotene cream vs vehicle cream.
Subject: 8511-004 | Age: 16 | Gender: Female

See real results

Image

HELP YOUR PATIENTS SAVE ON THIS INNOVATIVE ACNE TREATMENT.

patient savings card

*Indicating a 2-week time frame until results on the face; a 4-week time frame until results on the trunk.1

Reference: 1. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 µg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Please see full Important Safety Information below.

Scroll to ISI